PDF(Pubmed)
Abstract：
The life expectancy of our pets has been getting longer in recent years due to new therapeutic opportunities, better nutrition, and better diagnostic approaches. This positive effect, however, has been accompanied by a concomitant increase in neoplasms, particularly in canine patients. Therefore, veterinarians inevitably face new issues related to these diseases, poorly or never investigated in the past, such as the possible side effects resulting from chemotherapy. The aim of this study was to investigate whether and how chemotherapy influences the antibody response against CPV-2, CDV, and CAdV-1 in dogs vaccinated before starting chemotherapy. Twenty-one canine patients with different types of malignancies were sampled before, during, and after different chemotherapy protocols to determine their actual levels of seroprotection against CPV-2, CDV, and CadV-1 by using the in-practice test VacciCheck. Differences related to sex, breed size, type of tumor, and chemotherapy protocol were evaluated. No statistically significant changes in antibody protection emerged for any of the chemotherapy protocol used, suggesting that, contrary to expectation, chemotherapy does not have a marked immunosuppressive effect on the post-vaccine antibody response. These results, although preliminary, may be useful in improving the clinical approach to the canine cancer patient, helping veterinarians fully manage their patients, and enabling owners to feel more confident about their pets\' quality of life.
摘要：
近年来，由于新的治疗机会，我们宠物的预期寿命越来越长，更好的营养，和更好的诊断方法。这种积极的影响，然而,伴随着肿瘤的增加，特别是在犬类患者中。因此,兽医不可避免地面临与这些疾病有关的新问题，过去调查不佳或从未调查过，例如化疗可能产生的副作用。这项研究的目的是调查化疗是否以及如何影响抗CPV-2，CDV，和在开始化疗前接种疫苗的狗的CAdV-1。21名不同类型恶性肿瘤的犬科患者之前进行了采样，during,并在不同的化疗方案后确定其针对CPV-2，CDV的实际血清保护水平，和CadV-1通过使用实践测试VacciCheck。与性别有关的差异，品种大小,肿瘤类型,和化疗方案进行了评估。对于使用的任何化疗方案，抗体保护没有出现统计学上的显著变化，这表明，与预期相反，化疗对疫苗后抗体反应没有明显的免疫抑制作用.这些结果,虽然是初步的，可能有助于改善犬癌患者的临床治疗方法，帮助兽医充分管理他们的病人，并使主人对宠物的生活质量更有信心。
